Open Nav

Please submit your session questions in advance at http://bit.ly/BIOCEO19question

Are Record Levels of IPOs Still Disrupting M&A Deals?

In 2018, biotechs delivered the second-best year for public issuances ever. The attractive IPO market has however resulted in fewer M&A deals than prior years, with high pre-money IPO valuations for later-stage companies making it less enticing for them to accept early-exit offers. This has led to an M&A shift to focus on early-stage companies. How are changing valuations and exit options affecting venture investors? How are prospective buyers changing their deal terms? The session will examine the recent deal and market trends while highlighting the path forward amid a market with greatly increased volatility and reimbursement policy uncertainty.

Moderator: Lydia Ramsey, Senior Reporter, Business Insider

  • Date:Tuesday, February 12
  • Time:4:00 PM - 4:55 PM
  • Room:Shubert Complex
  • Location:6th Floor
  • Session Type:Educational Panel
  • Please submit your session questions in advance:

    Click here.

Speakers
Lydia Ramsey
Business Insider
John Chambers
H.C. Wainwright & Co., LLC
Jie D'Elia
Bristol-Myers Squibb
Craig Farrell
AlphaSense
Chris Garabedian
Xontogeny; Perceptive Advisors
Jim Healy
Sofinnova
Dennis J. Purcell
Aisling Capital LLC
Back